56620-43-0

Basic information

• Product Name: 1-Propyne, 3-isocyanato-
• Synonyms: 1-Propyne, 3-isocyanato-;3-isocyanatoprop-1-yne
• CAS NO: 56620-43-0
• Molecular Formula: C₄H₃NO
• Molecular Weight: 81
• Mol File: 56620-43-0.mol

Chemical Properties

• Boiling Point: 82.9±23.0 °C(Predicted)
• Appearance: /
• Density: 0.83±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1-Propyne, 3-isocyanato-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propyne, 3-isocyanato-(56620-43-0)
• EPA Substance Registry System: 1-Propyne, 3-isocyanato-(56620-43-0)

Safety Data

• Hazardous Substances Data: 56620-43-0(Hazardous Substances Data)

Usage

Reactivity

highly reactive

Toxicity

toxic

Uses

synthesis of various organic compounds

Hazards

strong irritant properties, severe irritation to skin, eyes, and respiratory system

Reactivity with other chemicals

powerful alkylating agent, reacts with nucleophiles in organic synthesis

Potential applications

pharmaceuticals and agrochemicals

Safety measures

proper precautions and safety measures should be taken when working with 1-Propyne, 3-isocyanato-

Upstream product

• 590-28-3 potassium cyanate 
• 6165-76-0 propargyl p-toluenesulfonate 
• 2450-71-7 Propargylamine 
• 503-38-8 trichloromethyl chloroformate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 878412-94-3 N-(allyloxycarbonyl)prop-2-inylamine 
• 1383939-33-0 1,1-diphenyl-3-(prop-2-ynyl)urea 

Downstream Products

• 5221-62-5 propargyl urea 
• 101871-81-2 1-phenyl-3-(prop-2-yn-1-yl)urea 
• 942612-43-3 CHNC(N)NCOCCOOC₂H₅((C₇H₇NCH₃)CH₂CCC₆H₄NHCONHC₃H₃)(CH₂C₆H₃F₂) 
• 1383938-71-3 N-(4-methoxybenzyl)-4-oxo-3-(prop-2-ynyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 
• 1464-98-8 N-(prop-2-yn-1-yl)benzamide 

Relevant articles and documents

Supporting-Electrolyte-Free Anodic Oxidation of Oxamic Acids into Isocyanates: An Expedient Way to Access Ureas, Carbamates, and Thiocarbamates

We report a new electrochemical supporting-electrolyte-free method for synthesizing ureas, carbamates, and thiocarbamates via the oxidation of oxamic acids. This simple, practical, and phosgene-free route includes the generation of an isocyanate intermediate in situ via anodic decarboxylation of an oxamic acid in the presence of an organic base, followed by the one-pot addition of suitable nucleophiles to afford the corresponding ureas, carbamates, and thiocarbamates. This procedure is applicable to different amines, alcohols, and thiols. Furthermore, when single-pass continuous electrochemical flow conditions were used and this reaction was run in a carbon graphite Cgr/Cgr flow cell, urea compounds could be obtained in high yields within a residence time of 6 min, unlocking access to substrates that were inaccessible under batch conditions while being easily scalable.

Practical one-pot amidation of N -Alloc-, N -Boc-, and N -Cbz protected amines under mild conditions

A facile one-pot synthesis of amides from N-Alloc-, N-Boc-, and N-Cbz-protected amines has been described. The reactions involve the use of isocyanate intermediates, which are generated in situ in the presence of 2-chloropyridine and trifluoromethanesulfonyl anhydride, to react with Grignard reagents to produce the corresponding amides. Using this reaction protocol, a variety of N-Alloc-, N-Boc-, and N-Cbz-protected aliphatic amines and aryl amines were efficiently converted to amides with high yields. This method is highly effective for the synthesis of amides and offers a promising approach for facile amidation.

THERAPEUTIC COMPOUNDS

The invention provides a product which is a compound of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof: (I) wherein: X is selected from: hydrogen; a methyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl; and an ethyl group which is either unsubstituted or is substituted with from one to five F substituent groups; Y is selected from: hydrogen; a methyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl; and an ethyl group which is either unsubstituted or is substituted with from one to five F substituent groups; RA is hydrogen, or is a C1-2 alkyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl.

ALIPHATIC PROLINAMIDE DERIVATIVES

This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG

Compounds of formula (I) and pharmaceutically acceptable salts, hydrates or solvates thereof are provided (I) wherein B, X, and Y are as defined herein. The compounds are of use in methods of regulating cell proliferation, inhibiting cell cycle progressio

N-(Propargyl)diazenecarboxamides for 'click' conjugation and their 1,3-dipolar cycloadditions with azidoalkylamines in the presence of Cu(II)

Propargyl functionalized diazenes 1 were prepared by two different approaches and were examined as alkyne click components in copper-catalyzed azide-alkyne cycloadditions (CuAAC) with 2-(azidomethyl)pyridine 5a and four α-azido-ω-aminoalkanes C2-C5 (5b-e)

3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

Synthesis and evaluation of homo-bivalent GnRHR ligands

G protein coupled receptors (GPCRs) are important drug targets in pharmaceutical research. Traditionally, most research efforts have been devoted towards the design of small molecule agonists and antagonists. An interesting, yet poorly investigated class of GPCR modulators comprise the bivalent ligands, in which two receptor pharmacophores are incorporated. Here, we set out to develop a general strategy for the synthesis of bivalent compounds that are projected to bind to the human gonadotropin-releasing hormone receptor (GnRHR). Our results on the dimerisation of a known GnRHR antagonist, with as key step the Huisgen 1,3-cycloaddition, and their ability to bind to and antagonize GnRH-induced GnRHR stimulation, are presented here.

Importance of the lipophilic group in carbamates having histamine H3- receptor antagonist activity

In order to evaluate changes in the lipophilic part of designed carbamates concerning their potential histamine H3-receptor antagonist properties a new series of O-[3-(1H-imidazol-4-yl)propanol]carbamates was derived containing N-mono- or dialkenyl, alkynyl, cycloalkyl, or double- branched alkyl substituents. The compounds were tested in vitro for their H3-receptor antagonist activity on synaptosomes of rat cerebral cortex and shared moderate to high antagonist activity in vitro. In this series 3-(1H- imidazol-4-yl)propyl N-(4-pentenyl)carbamate (4) was the most potent compound in vitro (K(i) = 6.3 nM). H3-receptor antagonist activity in the central nervous system (CNS) was detected for most compounds in the in vivo H3- receptor assay based upon measurement of brain N(τ)-methylhistamine levels after p.o. administration to mice. The most effective carbamate in vivo, 3- (1H-imidazol-4-yl)propyl N-(allyl)carbamate (3), showed higher CNS potency (ED50 = 0.48 mg/kg p.o.) than the reference antagonist thioperamide. For some novel carbamates their histamine H1- and H2-receptor activities were determined on isolated organs of guinea-pig thereby demonstrating their high H3-receptor selectivity.